Abstract
Demonstration of the efficacy of interferon beta IB in the reduction of outbreaks of multiple sclerosis has led to it being used in Spain. Discussion of the current situation regarding the use of interferon beta IB in Spain, diagnostic criteria, side-effects and future outlook. Use of interferon beta IB in Spain has followed criteria established by a Committee of Experts, and there is a lower rate of non-completion of treatment than in the U.S.A. New possibilities arise with the appearance of new drugs which are still awaiting evaluation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
